Skip to content

US · SANA · BIOTECHNOLOGY

Sana Biotechnology, Inc. (SANA) intrinsic value and stock valuation

$1.59as of 2026-11-21 · Mkt cap 976.8M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Sana Biotechnology, Inc. DCF and intrinsic value

InvestorsCraft values SANA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SANA’s statements →

Sana Biotechnology, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Seattle, WA 98102 sana.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-244.17M
20182025
Free cash flow
-$-144.77M
20182025
Total equity
$160.9M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-190.96M-$-272.72M-$-293.14M-$-272.56M-$-356.91M
Net income-$-244.17M-$-266.76M-$-283.25M-$-269.48M-$-355.93M
EPSd-$-964.22K-$-1.16M-$-1.46M-$-1.43M-$-2.14M
Operating cash flow-$-143.83M-$-223.15M-$-253.58M-$-290.05M-$-251.05M
Capital expenditure-$-940K-$-33.43M-$-20.03M-$-20.88M-$-29.86M
Free cash flow-$-144.77M-$-256.58M-$-273.61M-$-310.93M-$-280.92M
Total assets$416.9M$501M$565.3M$822.7M$1.13B
Total debt$78.9M$94.2M$104.1M$108.3M$110.9M
Net debt$6.99M-$-33.37M-$-29.42M-$-68.51M-$-142.09M
Total equity$160.9M$250.5M$287.5M$499.3M$728.5M
Cash and short-term investments$138.4M$152.5M$205.2M$424M$551M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$12.8M$0.00$0.00$0.00$0.00
Gross profit-$-12.75M$0.00$0.00$0.00$0.00
Research and development expenses$132M$208.7M$219.8M$201M$306.5M
Selling, general and administrative expenses$44.3M$64M$73.3M$71.6M$50.4M
Other expenses$1.93M$0.00$0.00$0.00$0.00
Operating expenses$178.2M$272.7M$293.1M$272.6M$356.9M
Cost and expenses$191M$272.7M$293.1M$272.6M$356.9M
Interest income$3.85M$10.5M$9.94M$3.76M$680K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$12.8M$17.4M$24.6M$15.6M$11.1M
Ebitda-$-231.42M-$-249.37M-$-258.7M-$-253.85M-$-344.86M
Operating income-$-190.96M-$-272.72M-$-293.14M-$-272.56M-$-356.91M
Total other income/expenses, net-$-53.21M$5.96M$9.89M$3.09M$980K
Income before tax-$-244.17M-$-266.76M-$-283.25M-$-269.48M-$-355.93M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-244.17M-$-266.76M-$-283.25M-$-269.48M-$-355.93M
Weighted average shares outstanding$253.2M$230.9M$194.5M$188.3M$166.4M
Weighted average diluted shares outstanding$253.2M$230.9M$194.5M$188.3M$166.4M
Balance sheet
20252024202320222021
Cash and short-term investments$138.4M$152.5M$205.2M$424M$551M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$148.7M$160.8M$213.5M$444.4M$558.1M
Property, plant and equipment, net$65.2M$135.3M$145.6M$159.4M$161.8M
Goodwill and intangible assets$199.8M$199.8M$199.8M$199.8M$199.8M
Long-term investments$0.00$0.00$0.00$10.1M$195.9M
Total non-current assets$268.2M$340.2M$351.8M$378.3M$571.3M
Total assets$416.9M$501M$565.3M$822.7M$1.13B
Accounts payable$1.67M$5.21M$4.11M$2.86M$2.22M
Short-term debt$14.9M$12.5M$13.2M$12.4M$9.16M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$78.7M$45.4M$64.5M$111.5M$99.2M
Long-term debt$63.9M$81.7M$90.9M$95.9M$101.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$177.3M$205.1M$213.3M$211.9M$301.7M
Capital lease obligations$78.9M$94.2M$104.1M$108.3M$110.9M
Total liabilities$256M$250.5M$277.8M$323.4M$400.9M
Common stock$30K$20K$20K$20K$20K
Retained earnings-$-1.85B-$-1.6B-$-1.34B-$-1.05B-$-785.36M
Accumulated other comprehensive income (loss)$30K$10K-$-60K-$-4.33M-$-1.37M
Total equity$160.9M$250.5M$287.5M$499.3M$728.5M
Total investments$66.5M$24.9M$71.7M$257.3M$493.9M
Total debt$78.9M$94.2M$104.1M$108.3M$110.9M
Net debt$6.99M-$-33.37M-$-29.42M-$-68.51M-$-142.09M
Cash flow statement
20252024202320222021
Net income-$-244.17M-$-266.76M-$-283.25M-$-269.48M-$-355.93M
Depreciation and amortization$12.8M$17.4M$24.6M$15.6M$11.1M
Stock-based compensation$25.5M$37.7M$35.5M$38.3M$22.4M
Change in working capital-$-10.11M-$-1.19M$18.6M$7.54M$9.8M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-3.54M$1.38M$1.03M$1.06M-$-270K
Net cash provided by operating activities-$-143.83M-$-223.15M-$-253.58M-$-290.05M-$-251.05M
Investments in property, plant and equipment-$-940K-$-33.43M-$-20.03M-$-20.88M-$-29.86M
Acquisitions, net$1.43M$0.00-$-190K-$-230K$0.00
Net cash used for investing activities-$-40.24M$17.5M$172M$210.6M-$-245.8M
Common stock issued$129.1M$181M$31.7M$4.91M$631.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$128.7M$199.8M$31.7M$4.91M$631.8M
Net change in cash-$-55.33M-$-5.95M-$-49.92M-$-74.58M$134.9M
Cash at end of period$76.1M$131.4M$137.4M$187.3M$261.9M
Operating cash flow-$-143.83M-$-223.15M-$-253.58M-$-290.05M-$-251.05M
Capital expenditure-$-940K-$-33.43M-$-20.03M-$-20.88M-$-29.86M
Free cash flow-$-144.77M-$-256.58M-$-273.61M-$-310.93M-$-280.92M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sana Biotechnology, Inc.

        Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.

        CEO
        Steven D. Harr
        Employees
        142
        Beta
        2.14

        Explore

        Frequently asked questions

        What is the intrinsic value of Sana Biotechnology, Inc. (SANA)?

        InvestorsCraft does not currently publish an intrinsic value for SANA. How the IC value is calculated.

        Is SANA undervalued?

        InvestorsCraft does not publish an undervaluation signal for SANA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.